Assessment of the National French recommendations regarding the dosing regimen of 8 mg/kg of gentamicin in patients hospitalised in intensive care units

Anaesthesia Critical Care and Pain Medicine

Volumn 35, Issue 5, 2016, Pages 331-335

  Allou, Nicolas ^a   Allyn, Jérôme ^a   Levy, Yaël ^a   Bouteau, Astrid ^b   Caujolle, Marie ^a   Delmas, Benjamin ^a   Valance, Dorothée ^a   Brulliard, Caroline ^a   Martinet, Olivier ^a   Vandroux, David ^a   Montravers, Philippe ^b   Augustin, Pascal ^b  

^a CHR Felix Guyon   (France)

^b Section of Radiology   (France)

Author keywords

Gentamicin; Intensive care unit; Pharmacokinetics pharmacodynamics; Severe sepsis septic shock

Indexed keywords

GENTAMICIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENTEROBACTERIACEAE; FEMALE; FERMENTATION; FLUID BALANCE; FRENCH NATIONAL AGENCY FOR MEDICINES AND HEALTH PRODUCTS SAFETY GUIDELINE; HOSPITAL PATIENT; HUMAN; INFECTION; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROGNOSIS; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SIMPLIFIED ACUTE PHYSIOLOGY SCORE 2; STAPHYLOCOCCUS; ALGORITHM; APACHE; DRUG EFFECTS; ELECTROLYTE BALANCE; FRANCE; HOSPITALIZATION; INTENSIVE CARE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MORTALITY; SEPSIS; SHOCK, SEPTIC; STANDARDS;

AGED; ALGORITHMS; ANTI-BACTERIAL AGENTS; APACHE; COHORT STUDIES; CRITICAL CARE; ENTEROBACTERIACEAE; FEMALE; FRANCE; GENTAMICINS; GUIDELINES AS TOPIC; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; SEPSIS; SHOCK, SEPTIC; WATER-ELECTROLYTE BALANCE;

EID: 84995579242     PISSN: None     EISSN: 23525568     Source Type: Journal    
DOI: 10.1016/j.accpm.2015.12.012     Document Type: Article

References (18)

1. [1] Dellinger, R.P., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 39 (2013), 165–228.
2. [2] Kumar, A., Safdar, N., Kethireddy, S., Chateau, D., A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med 38 (2010), 1651–1654.
3. [3] Kumar, A., Zarychanski, R., Light, B., Parrillo, J., Maki, D., Simon, D., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 38 (2010), 1773–1785.
4. [4] Moore, R.D., Lietman, P.S., Smith, C.R., Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155 (1987), 93–99.
5. [5] Agence française de sécurité sanitaire des produits de santé, Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med Mal Infect 42 (2012), 301–308.
6. [6] European Committee on Antimicrobial Susceptibility Testing (EUCAST). http://www.eucast.org/. 2015.
7. [7] von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke, J.P., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
8. [8] Blaser, J., Konig, C., Fatio, R., Follath, F., Cometta, A., Glauser, M., Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ther Drug Monit 17 (1995), 133–136.
9. [9] Goncalves-Pereira, J., Martins, A., Povoa, P., Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect 16 (2010), 1258–1263.
10. [10] Buijk, S.E., Mouton, J.W., Gyssens, I.C., Verbrugh, H.A., Bruining, H.A., Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28 (2002), 936–942.
11. [11] Demczar, D.J., Nafziger, A.N., Bertino, J.S. Jr., Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 41 (1997), 1115–1119.
12. [12] Marik, P.E., Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 21 (1993), 172–173.
13. [13] Dubois, V., Arpin, C., Dupart, V., Scavelli, A., Coulange, L., Andre, C., Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). J Antimicrob Chemother 62 (2008), 316–323.
14. [14] Rea, R.S., Capitano, B., Bies, R., Bigos, K.L., Smith, R., Lee, H., Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 30 (2008), 674–681.
15. [15] Phillips, J.A., Bell, S.C., Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Intern Med J 31 (2001), 23–26.
16. [16] Schmitz, F.J., Verhoef, J., Fluit, A.C., Prevalence of aminoglycoside resistance in 20 European university hospitals participating in the European SENTRY Antimicrobial Surveillance Programme. Eur J Clin Microbiol Infect Dis 18 (1999), 414–421.
17. [17] de Montmollin, E., Bouadma, L., Gault, N., Mourvillier, B., Mariotte, E., Chemam, S., et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med 40 (2014), 998–1005.
18. [18] Taccone, F.S., Laterre, P.F., Spapen, H., Dugernier, T., Delattre, I., Layeux, B., et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care, 14, 2010, R53.